Galena Biopharma (GALE) Receives Notice of Allowance for US Patent Related to NeuVax
Tweet
Share
E-mailGet Alerts GALE Hot Sheet
Join SI Premium – FREE
Galena Biopharma, Inc. (Nasdaq: GALE) today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent covering the use of its product candidate, NeuVax™, a HER2/neu peptide vaccine, for inducing immunity to breast cancer recurrence in patients having low-to-intermediate IHC ratings of 1+ or 2+ and a FISH rating of less than about 2.0. These patients represent a significant unmet medical need, with as much as 50-75% of breast cancer patients who do not qualify for Herceptin® therapy.
"This NeuVax patent reinforces its pioneering role in advancing treatment to reduce recurrence rates for breast cancer survivors," stated Mark J. Ahn, Ph.D., President and CEO. "This addition to our global portfolio allows us to further strengthen our value proposition and explore additional uses for NeuVax to advance care and build value for patients and shareholders."
"This NeuVax patent reinforces its pioneering role in advancing treatment to reduce recurrence rates for breast cancer survivors," stated Mark J. Ahn, Ph.D., President and CEO. "This addition to our global portfolio allows us to further strengthen our value proposition and explore additional uses for NeuVax to advance care and build value for patients and shareholders."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Synaptics CFO resigns amid pending ON Semiconductor merger
- Veeva Systems names Dan Rizzo EVP of sales amid leadership change
- Cinemo, Dolby, and SmashLabs partner on in-car gaming system
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
